DeepMed Research

SSGJ-626

Generic Name: SSGJ-626

Clinical Trials

Evaluation of 626 in Healthy Adult Subjects

Phase 1

Recruiting

Conditions: Healthy Subjects (HS)

Interventions: Drug: 626
Drug: Placebo

First Posted Date: 2024-11-05

Last Posted Date: 2024-12-10

Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Target Recruit Count: 50

Registration Number: NCT06674525

Locations: 🇨🇳
Shanghai General Hospital, Shanghai, China

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy